Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
29
XBIT Quote, Financials, Valuation and Earnings
Last price:
$2.34
Seasonality move
:
9.81%
Day range:
$2.30 - $2.45
52-week range:
$2.09 - $3.62
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
22.19x
P/B ratio:
0.42x
Volume:
22.8K
Avg. volume:
42.9K
1-year change:
-25.96%
Market cap:
$70.4M
Revenue:
--
EPS (TTM):
-$0.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XBIT
XBiotech, Inc.
|
-- | -- | -- | -- | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$298.6M | $0.20 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.3B | $2.18 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$848.4M | $1.32 | 11.9% | 36.21% | $88.87 |
|
IMNN
Imunon, Inc.
|
-- | -$0.74 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XBIT
XBiotech, Inc.
|
$2.31 | -- | $70.4M | -- | $0.00 | 0% | 22.19x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$64.08 | $88.87 | $12.3B | 24.01x | $0.00 | 0% | 4.06x |
|
IMNN
Imunon, Inc.
|
$3.22 | $21.50 | $6.8M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$5.53 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XBIT
XBiotech, Inc.
|
-- | 0.007 | -- | 41.34x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XBIT
XBiotech, Inc.
|
-$427K | -$6M | -16.03% | -16.39% | -- | -$4.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
XBiotech, Inc. vs. Competitors
-
Which has Higher Returns XBIT or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to XBiotech, Inc.'s net margin of 25.76%. XBiotech, Inc.'s return on equity of -16.39% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital XBITXBiotech, Inc.-- -$0.20 $167.1M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About XBIT or ACAD?
XBiotech, Inc. has a consensus price target of --, signalling upside risk potential of 679.22%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 30.1%. Given that XBiotech, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe XBiotech, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBITXBiotech, Inc.0 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is XBIT or ACAD More Risky?
XBiotech, Inc. has a beta of 0.861, which suggesting that the stock is 13.92% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock XBIT or ACAD?
XBiotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XBiotech, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIT or ACAD?
XBiotech, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. XBiotech, Inc.'s net income of -$6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, XBiotech, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XBiotech, Inc. is 22.19x versus 3.86x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBITXBiotech, Inc.22.19x -- -- -$6M ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M
-
Which has Higher Returns XBIT or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to XBiotech, Inc.'s net margin of 16.99%. XBiotech, Inc.'s return on equity of -16.39% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital XBITXBiotech, Inc.-- -$0.20 $167.1M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About XBIT or ALNY?
XBiotech, Inc. has a consensus price target of --, signalling upside risk potential of 679.22%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that XBiotech, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe XBiotech, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBITXBiotech, Inc.0 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is XBIT or ALNY More Risky?
XBiotech, Inc. has a beta of 0.861, which suggesting that the stock is 13.92% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock XBIT or ALNY?
XBiotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XBiotech, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIT or ALNY?
XBiotech, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. XBiotech, Inc.'s net income of -$6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, XBiotech, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XBiotech, Inc. is 22.19x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBITXBiotech, Inc.22.19x -- -- -$6M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns XBIT or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to XBiotech, Inc.'s net margin of -3.91%. XBiotech, Inc.'s return on equity of -16.39% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital XBITXBiotech, Inc.-- -$0.20 $167.1M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About XBIT or BMRN?
XBiotech, Inc. has a consensus price target of --, signalling upside risk potential of 679.22%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.87 which suggests that it could grow by 38.69%. Given that XBiotech, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe XBiotech, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBITXBiotech, Inc.0 0 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is XBIT or BMRN More Risky?
XBiotech, Inc. has a beta of 0.861, which suggesting that the stock is 13.92% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock XBIT or BMRN?
XBiotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XBiotech, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIT or BMRN?
XBiotech, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. XBiotech, Inc.'s net income of -$6M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, XBiotech, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 24.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XBiotech, Inc. is 22.19x versus 4.06x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBITXBiotech, Inc.22.19x -- -- -$6M BMRNBioMarin Pharmaceutical, Inc.4.06x 24.01x $786.8M -$30.7M
-
Which has Higher Returns XBIT or IMNN?
Imunon, Inc. has a net margin of -- compared to XBiotech, Inc.'s net margin of --. XBiotech, Inc.'s return on equity of -16.39% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital XBITXBiotech, Inc.-- -$0.20 $167.1M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About XBIT or IMNN?
XBiotech, Inc. has a consensus price target of --, signalling upside risk potential of 679.22%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 567.7%. Given that XBiotech, Inc. has higher upside potential than Imunon, Inc., analysts believe XBiotech, Inc. is more attractive than Imunon, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBITXBiotech, Inc.0 0 0 IMNNImunon, Inc.3 1 0 -
Is XBIT or IMNN More Risky?
XBiotech, Inc. has a beta of 0.861, which suggesting that the stock is 13.92% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock XBIT or IMNN?
XBiotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XBiotech, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIT or IMNN?
XBiotech, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. XBiotech, Inc.'s net income of -$6M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, XBiotech, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XBiotech, Inc. is 22.19x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBITXBiotech, Inc.22.19x -- -- -$6M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns XBIT or SVRA?
Savara, Inc. has a net margin of -- compared to XBiotech, Inc.'s net margin of --. XBiotech, Inc.'s return on equity of -16.39% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital XBITXBiotech, Inc.-- -$0.20 $167.1M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About XBIT or SVRA?
XBiotech, Inc. has a consensus price target of --, signalling upside risk potential of 679.22%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that XBiotech, Inc. has higher upside potential than Savara, Inc., analysts believe XBiotech, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings XBITXBiotech, Inc.0 0 0 SVRASavara, Inc.6 0 0 -
Is XBIT or SVRA More Risky?
XBiotech, Inc. has a beta of 0.861, which suggesting that the stock is 13.92% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock XBIT or SVRA?
XBiotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XBiotech, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XBIT or SVRA?
XBiotech, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. XBiotech, Inc.'s net income of -$6M is higher than Savara, Inc.'s net income of -$29.6M. Notably, XBiotech, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XBiotech, Inc. is 22.19x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XBITXBiotech, Inc.22.19x -- -- -$6M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
